Weinshenker, David 1 Curriculum Vitae Name: David Weinshenker, Ph.D. Office Address: Revised 7/8/16 Department of Human Genetics Emory University School of Medicine Whitehead Building, Suite 301 615 Michael St. Atlanta, GA 30322 Phone: (404) 727-3106 Fax: (404) 727-3949 Email Address: [email protected]; [email protected]Citizenship: US citizen Current Titles and Affiliations: Academic appointments: I. Primary appointments: Assistant Professor, Department of Human Genetics, Emory University School of Medicine, 2002-2008 Associate Professor, Department of Human Genetics, Emory University School of Medicine, 2008-2012 Professor, Department of Human Genetics, Emory University School of Medicine, 2013-present Education: 1987-1992 BA, Psychobiology, University of California, Santa Cruz 1992-1997 Graduate student, Department of Genetics, University of Washington, Seattle, WA, James H. Thomas, advisor, Ph.D. received December, 1997 Postgraduate Training: Postdoctoral research fellow, Howard Hughes Medical Institute and Department of Biochemistry, University of Washington, Seattle, WA, Richard D. Palmiter, advisor
Transcript
Weinshenker, David 1Curriculum Vitae
Name: David Weinshenker, Ph.D.
Office Address: Revised 7/8/16Department of Human GeneticsEmory University School of MedicineWhitehead Building, Suite 301615 Michael St.Atlanta, GA 30322Phone: (404) 727-3106Fax: (404) 727-3949
Current Titles and Affiliations:Academic appointments:
I. Primary appointments: Assistant Professor, Department of Human Genetics, Emory University School of Medicine, 2002-2008
Associate Professor, Department of Human Genetics, Emory University School of Medicine, 2008-2012
Professor, Department of Human Genetics, Emory University School of Medicine, 2013-present
Education:1987-1992 BA, Psychobiology, University of California, Santa Cruz1992-1997 Graduate student, Department of Genetics, University of Washington, Seattle, WA,
James H. Thomas, advisor, Ph.D. received December, 1997
Postgraduate Training: Postdoctoral research fellow, Howard Hughes Medical Institute and Department of Biochemistry, University of Washington, Seattle, WA,
Richard D. Palmiter, advisor January 1998 – March 2002
Committee Memberships (Institutional):2002-2005 Voting member, Emory Institutional Animal Care and Use Committee (IACUC)2003-2007 Chair, Department of Human Genetics Annual Retreat Committee2004-2006 Emory Parkinson’s Disease Center Steering Committee2005-present Executive Committee, Neuroscience Graduate Program 2005-2014 Executive Committee, Molecular/Systems Pharmacology Graduate Program2007-present Emory Animal Resources Advisory Committee2007-2011 Emory Neurosciences Initiative Research Committee2008-2014 Director of Graduate Studies, Molecular/Systems Pharmacology Graduate
Program2010-2014 Steering Committee, Emory University NIDA T32 training grant2010-2014 Steering Committee, Molecular/Systems Pharmacology training grant2010-present Emory School of Medicine Research Advisory Committee2010-2013 Emory School of Medicine Faculty Committee on Appointments and Promotions
Weinshenker, David 22012-2013 Department of Human Genetics Faculty Search Committee2013 Emory IACUC Subcommittee on Monitoring of Genetically Modified Animal Models2014-present Department of Human Genetics Faculty Committee on Appointments and Promotions2014-present Emory School of Medicine Bridge Funding Committee2015-present Emory School of Medicine Catalyst and Seed Funding Committee2015-present Emory School of Medicine Promotions Readiness Advisory Committee2015-present Emory School of Medicine Dean’s Faculty Advisory Committee2015-present Director, Emory Neuroscience Graduate Program
Core Facilities2009-present Founder and Scientific Director, Emory School of Medicine Rodent Behavioral Core Facility
Editorships and Editorial Boards:2006-2012 Editorial Advisory Board, Biochemical Pharmacology2007 Guest Editor, special Drug Addiction issue of Biochemical Pharmacology2010-present Associate Editor, Journal of Pharmacology and Experimental Therapeutics2014-present Editorial Board, Molecular Pharmacology
Manuscript Reviewer:Addiction BiologyAmerican Journal of Human GeneticsAnnals of Clinical and Translational NeurologyArchives of General PsychiatryBehavioral PharmacologyBiochemical PharmacologyBiological PsychiatryBrainBrain ResearchBrain SciencesEpilepsy ResearchEuropean NeuropsychopharmacologyInternational Journal of NeuropsychopharmacologyJournal of Neural TransmissionJournal of NeurochemistryJournal of NeuroscienceJournal of Neuroscience ResearchJournal of Pharmacology and Experimental TherapeuticsJournal of Pharmacy and PharmacologyLetters in Drug Design and DiscoveryMolecular PharmacologyMolecular PsychiatryNature CommunicationsNeurobiology of AgingNeuronNeuropeptidesNeuropharmacologyNeuropsychopharmacologyNeuroscience
Weinshenker, David 3Neuroscience Letters Pharmacogenetics and GenomicsPharmacology, Biochemistry, and BehaviorPLoS OneProceedings of the National Academy of Sciences, USAProgress in Neuro-Psychopharmacology & Biological PsychiatryPsychoneuroendocrinologyPsychopharmacologySleep Medicine Reviews
Grant Reviewer2004 The Wellcome Trust 2009 Ad hoc grant reviewer for NIH ZRG1 BDCN-T (03) Study Section 2009 Ad hoc grant reviewer for NIH NMB Study Section 2010-present Ad hoc grant reviewer for the Alzheimer’s Association2010-2014 Ad hoc grant reviewer for King Abdulaziz City for Science and Technology
(KACST), administered by the American Association for the Advancement of Science (AAAS)
2011 Ad hoc grant reviewer for the University of Alabama-Birmingham Center for Clinical and Translational Science
2011-2012 Ad hoc grant reviewer for the French National Research Agency (ANR)2012 Ad hoc grant reviewer for the Michael J. Fox Foundation2012 Ad hoc grant reviewer for NIH ZRG1 IFCN-C (02) Study Section2013 Ad hoc grant reviewer for NIH ANIE Study Section2014 Ad hoc grant reviewer for The Wellcome Trust Strategic Awards2015 Ad hoc grant reviewer for NIH ZRG1 F02A-J Study Section2016 Ad hoc grant reviewer for NIH ZRG1 BBBP-V (02) M Study Section
Honors and Awards: 2004 National Alliance on Research for Schizophrenia and Depression Young Investigator’s
Award2010 Emory Graduate Division of Biological and Biomedical Sciences Mentor of the Year Award2014 Emory Graduates in Neuroscience Faculty of the Year Award2015 Emory School of Medicine 1% Award (for 1% score on an NIH grant)2016 Emory School of Medicine Outstanding Postdoc Mentor Award
Society Memberships: 1998-present Society for Neuroscience2006–2010, 2016-present Councilor, Atlanta Chapter Society for Neuroscience
Research Focus: We use genetically engineered mice and rats with altered noradrenergic systems to study how norepinephrine influences various aspects of physiology, behavior, and neurochemistry. Our main areas of interest are drug addiction, neurodegenerative disease, epilepsy, and depression.
Patents1. Provisional Application, Serial No. 60/702,078 titled “Compositions and Methods of Noradrenergic Control of Torpor”. This patent describes the use of noradrenergic compounds to induce and suppress hibernative states.
Weinshenker, David 4
2. Patent filed 10/2/12, Serial No. 13/633,397, publication number US-2013-0274302-A1 titled “Methods and Compositions for Treatment of Drug Addiction”. This patent describes the use of selective dopamine -hydroxylase inhibitors for the treatment of stimulant dependence.
Grant Support:a. Active support
I. Federally funded:
5RO1DA038453-02 (NIH/NIDA) Weinshenker/Paladini (MPI) 4/1/15-12/31/19Role: MPI, 2.4 calendarYear 1 Direct Costs: $266,347Mechanisms of cocaine hypersensitivity following chronic DBH inhibitionThe goal of this project is to explore the contribution of -arrestin2 and a switch in D2 receptor G protein coupling to cocaine hypersensitivity and aversion produced by chronic inhibition of norepinephrine production.
1RF1AG0476670-01 (NIH/NIA) Weinshenker (PI) 7/1/14-6/30/19Role: PI, 2.4 calendarConsequences of Locus Coeruleus Activation in a Rat Model of Alzheimer’s DiseaseCurrent Year Direct Costs: $225,000 The goal of this project is to determine whether optogenetic activation of locus coeruleus neurons can ameliorate Alzheimer’s disease-like neuropathology and cognitive deficits in a transgenic rat model.
1 R21 DA040788-01A1 (NIH/NIDA) Weinshenker (PI) 7/1/16-6/30/18 Role: PI, 1.80 calendar monthsCurrent Year Direct Costs: $150,000 Neurobiology of reward choiceThe goal of this project to determine whether increasing the salience/value of a natural reward can shift behavior a novel food vs. cocaine choice procedure.
1RO1GM097331-01 (NIH/NIGMS) Warren/Caspary/Weinshenker (MPI) 3/5/12-1/31/16Role: MPI, 1.8 calendarCurrent Year Direct Costs: $269,195Characterization of the Schizophrenia-associated 3q29 Deletion in MouseThe major goal of this project is to generate and characterize mice bearing a 3q29 deletion that increases the risk of schizophrenia and intellectual disability in humans, and to identify the gene(s) within that interval responsible for the phenotypes.
1P50NS071669-01 (NIH/NINDS) Wichmann (PI) 4/26/16-4/25/17 Role: MPI of Pilot Project, 0.12 calendar
Weinshenker, David 5Annual Direct Costs (Pilot Project): $30,000 Pilot Project of the Emory Udall Parkinson’s Disease Center (Center director: Thomas Wichmann) Pilot Project: A novel approach to test the role of alpha-synuclein in locus coeruleus vulnerability to degeneration and seeding pathology in PD (Tansey, PI)The major goal of this pilot project is to determine whether transgenic overexpression of human alpha-synuclein in the mouse locus coeruleus promotes noradrenergic neuron degeneration and spread of pathology to other parts of the brain.
2R01AG033678-06A1 Boyle (PI) 8/1/15-4/30/20Role: Co-I, 0.6 calendarCurrent Year Direct Costs for Subcontract: $17,616Epidemiologic Study of Decision Making in Preclinical Alzheimer’s DiseaseThe goal of this project is to determine the causes and consequences of age-related changes in decision making over time.1R21NS098776-01 (NIH/NINDS) Escayg (PI) 5/12/16-5/31/18NIH/NINDSRole: Co-ICurrent Year Direct Costs: $150,000Toward the development of an effective treatment for SCN1A derived epilepsy.The goal of this project is to develop pharmacotherapies in mice for epilepsy caused by sodium channel gene mutations.
2P30NS055077-06A1 Levey (PI) 8/1/15-6/30/19Role: Scientific Director, Rodent Behavioral Core, 0.6 calendarCurrent Year Direct Costs for Behavioral Core: $60,589Emory Neuroscience NINDS Core Facilities (ENNCF)The goal of this project is to maintain and continue support for the Emory Neuroscience NINDS Core Facilities and provide consolidated resources and expertise to NINDS funded projects as well as projects aligned to the NINDS mission of reducing the burden of neurological diseases.
II. Foundation funded:
IIRG-13-278692 (Alzheimer’s Association) Weinshenker (PI) 9/1/13-8/31/16Role: PI, 0.6 calendarDoes Alzheimer’s disease pathogenesis begin in the locus coeruleus?Year 1 Direct Costs: $73,068The goal of this project is to assess the neurotoxicity and transmission of aberrant tau in the locus coeruleus.
b. Pending Support:
c. Previous Support:
1P50NS071669-01 (NIH/NINDS) Wichmann (PI) 5/1/15-4/30/16 Role: MPI of Pilot Project, 0 calendar Annual Direct Costs (Pilot Project): $30,000 Pilot Project of the Emory Udall Parkinson’s Disease Center (Center director: Thomas Wichmann)
Weinshenker, David 6Pilot Project: Contribution of Locus Coeruleus-Ventral Periaqueductal Gray Circuit Dysfunction to Sleepiness in Parkinson’s DiseaseThe major goal of this pilot project is to determine whether the activation of vPAG dopamine neurons by locus coeruleus-derived norepinephrine promotes arousal and is dysfunctional in a mouse model of Parkinson’s disease.
R21 NS084229 Escayg (PI) 9/1/14-3/31/16Role: Co-I, 0.6 calendarCurrent Year Direct Costs: $150,000SCN1A Dysfunction and Neuropsychiatric ComorbiditiesThe goal of this project is to use Scn1a mutant mice to assess cognitive and behavioral outcomes associated with SCN1A dysfunction.
1RO3DA034867-01A1 (NIH/NIDA) Weinshenker (PI) 6/1/13-5/31/15Role: PI, 0.6 calendarAnnual Direct Costs: $50,000Reinstatement of cocaine seeking by social defeatThe goal of this project is to develop a rat model of cocaine relapse induced by psychosocial stress.
1RO1DA027535-03 (NIH/NIDA) Weinshenker/Holmes (MPI) 01/15/10-12/31/14Role: MPI, 2.4 calendarAnnual Direct Costs: $298,084Effects of voluntary exercise on reinstatement of cocaine seekingThe major goal of this project is to assess galanin-norepinephrine interactions underlying the ability of voluntary exercise to attenuate reinstatement of cocaine seeking in rats.
Role: PI of Project 3, 1.2 calendar Levey (PI) 05/01/10-04/30/15Annual Direct Costs (Project 3): $98,882Project 3 of the Emory Alzheimer’s Disease Research Center (Center director: Allan Levey)Project 3: Norepinephrine-TrkB Interactions in Alzheimer’s Disease.The goal of the Center is to establish clinical, pathologic, education, data management and administrative cores to support Alzheimer’s disease research and to support individual research projects into MCI, Alzheimer’s genetics and the application of proteomics technologies at Emory. The goal of Project 3 is to assess the neuroprotective effects of norepinephrine-TrkB interactions in Alzheimer’s disease.
1R21NS081461-01 (NIH/NINDS) Hall (PI) 9/24/12 – 8/31/14Role: Co-Investigator, 1.2 calendarAnnual Direct Costs: $150,000Activation of GPR37 and GPR37L1 by Prosaptide, a Neuroprotective PeptideThe goal of this project is to determine whether the the neuroprotective effects of prosaptide are mediated by the orphan G-protein coupled receptors, GPR37 and GPR37L1.
1 R21AI101472-01 (NIH/NIAID) Sperandio (PI) 7/1/12-6/30/14Role: Co-I, 0.6 calendarAnnual Direct Costs: $125,000 Host Pathogen Signaling in the IntestineThe major goal of this project was to characterize the contribution of host epinephrine and norepinephrine hormones to C. rodentium pathogenesis during murine infection.
Weinshenker, David 7
Alzheimer’s Disease Drug Discovery Foundation Weinshenker (Co-PI) 2012-2014ATX-001: A 12 month, Phase II Randomized, Double-Blind, Placebo Controlled, Flexible Dosing Trial of Atomoxetine in Subjects with Mild Cognitive Impairment.Role: Co-PIAnnual Direct Costs: $400,000The goal of this project is to test the effects of the norepinephrine reuptake inhibitor, atomoxetine, on Alzheimer’s disease biomarkers and cognitive status in individuals with mild cognitive impairment who are at high risk for progressing to Alzheimer’s disease.
1R21NS072712-01A1 (NIH/NINDS) Cubells (PI) 7/1/11-4/30/13Role: Co-Investigator, 1.8 calendarAnnual Direct Costs: $125,000Translational analysis of functional variation in human dopamine -hydroxylaseThe major goal of this project was to generate bacterial artificial chromosome transgenic mice bearing two different alleles of the human dopamine -hydroxylase gene and assess the effects of a putatively functional promoter single nucleotide polymorphism that associates with variation in plasma dopamine -hydroxylase activity.
5P01ES016731-04 (NIH/NIEHS) Weinshenker (PI) 7/1/12-6/30/13 Role: PI of Internal Pilot Project, 0.12 calendarAnnual Direct Costs: $25,000Internal Pilot Project of the Emory Parkinson’s Disease Collaborative Environmental Research Center (Center Director, Gary W. Miller)“The role of noradrenergic neurons in Parkinson’s disease”The overall goal of this application was to generate a transgenic mouse that overexpresses human A53T synuclein in noradrenergic neurons using a modified DBH-BAC transgenic approach.
5P01ES016731-04 (NIH/NIEHS) Weinshenker (Co-PI) 7/1/2011-6/30/12 Role: Co-PI, 0.24 calendar Annual Direct Costs: $25,000 Pilot Project of the Emory Parkinson’s Disease Collaborative Environmental Research Center (Center director: Gary W. Miller) The major goal of this pilot project was to determine whether stimulation of the parkin-associated endothelin-like receptor (Pael-R) exerts neuroprotective effects against MPTP-induced dopaminergic toxicity.
1R21NS060935-01 (NIH/NINDS) Thomas (PI) 9/15/07 – 8/31/10Role: Co-Investigator, 0.6 calendarAnnual Direct Costs: $150,000Comparative Genetics of Lesch-Nyhan DiseaseThe goal of this project was to create a mouse model of Lesch-Nyhan disease.
5R01DA017963-04 (NIH/NIDA) Weinshenker (PI) 4/10/06 – 3/31/10Role: PI, 3.6 calendarAnnual Direct Costs: $214,106Mechanism of Disulfiram-Induced Cocaine Abstinence
Weinshenker, David 8The major goals of this project were to (1) determine the effects of disulfiram on cocaine reward, aversion, and drug seeking in rodents, and (2) determine whether inhibition of dopamine -hydroxylase mediates the effects of disulfiram in these paradigms.
2RO1NS053444-04 (NIH/NINDS/NIDA) Weinshenker (PI) 07/15/05-02/28/09Role: PI, 3 calendarAnnual Direct Costs: $175,414A Rodent Model of Epilepsy and Depression Co-morbidityThe major goal of this project was to use selectively bred rats to determine the genetic basis of epilepsy and depression co-morbidity.
1R03DA019849-01 NIH/NIDA Weinshenker (PI) 8/1/05 –7/31/07Role: PI, 1.2 calendarAnnual Direct Costs: $50,000Disulfiram, DBH, and Cocaine-Induced AnxietyThe major goal of this project was to determine whether genetic or pharmacological inhibition of dopamine -hydroxylase alters cocaine-induced anxiety in mice.
260202 Alzheimer’s Drug Discovery Foundation Weinshenker (PI) 12/1/06 – 11/30/07Role: PI, 1.2 calendarAnnual Direct Costs: $90,887Noradrenergic Treatments for Alzheimer’s DiseaseThe goal of this project was to determine whether compounds that increase norepinephrine can suppress the neuropathology and cognitive deficits in a mouse model of Alzheimer’s disease.
5R03DA019955-02 (NIH/NIDA) Weinshenker (PI) 7/1/05 –7/31/07Role: PI, 1.2 calendarAnnual Direct Costs: $50,000Modeling Genetically Controlled DBH Activity in MiceThe major goal of this project was to use BAC transgenic mice to understand how human dopamine -hydroxylase polymorphisms modulate DBH enzymatic activity and behavior.
Cephalon Pharmaceuticals Weinshenker (PI) 11/30/04 – 12/31/07Role: PI, 1.2 calendarAnnual Direct Costs: $30,000 - $65,360Modafinil Locomotor Studies Using Norepinephrine Transporter Knockout (NET -/-) MiceThe major goal of this project was to use NET knockout mice to understand how NET blockade contributes to the psychomotor effects of the wake-promoting drug modafinil.
3P50AG025688-01S1 Levey (PI) 12/1/05 – 11/30/06 Role: PI of pilot project, 1.2 calendar (Levey, PI of Center)Annual Direct Costs: $25,000The Influence of Norepinephrine on Human and Mouse Alzheimer’s DiseaseThe main goal of this Alzheimer’s Disease Research Center pilot project was to determine whether loss of norepinephrine contributes to Alzherimer’s disease neuropathology and cognitive dysfunction in human cohorts and in mouse models.
Emory University Research Committee Weinshenker (PI) 1/30/05 – 1/30/06Role: PI, 1.2 calendar
Weinshenker, David 9Annual Direct Costs ($30,000)A Mouse Model of Human Dbh PolymorphismsThe major goal of this project was to use transgenic mice expressing various alleles of the human dopamine -hydroxylase (Dbh) gene to understand how Dbh polymorphisms control DBH enzymatic activity.
National Alliance for Research on Schizophrenia and Depression Weinshenker (PI) 7/1/04 – 6/30/06 Role: PI, 1.2 calendarAnnual Direct Costs: $30,000Norepinephrine: A Molecular Link Between Depression and EpilepsyThe major goal of this project was to use genetically engineered mice with altered noradrenergic function to understand how norepinephrine dysfunction contributes to epilepsy and depression co-morbidity.
Epilepsy Foundation Weinshenker (PI) 7/1/03 – 6/30/04Role: PI, 1.2 calendarAnnual Direct Costs: $40,000Control of Antiepileptic Drug Efficacy by NorepinephrineThe major goal of this project was to determine whether norepinephrine was critical for the full efficacy of anticonvulsant drugs.
Mentor/Sponsor for Individual Predoctoral or Postdoctoral Awards:
2003-2005 Brooke N. Bourdelat-Parks, Emory FIRST Postdoctoral Fellowship2006-2008 Jesse R. Schank, NIH F31 Predoctoral National Research Service Award2009-2011 Darlene A. Mitrano, Emory FIRST Postdoctoral Fellowship2008-2011 Meriem Gaval, NIH F31 Predoctoral National Research Service Award 2010-2012 S. Alisha Epps, NIH F31 Predoctoral National Research Service Award2012-2015 Yvonne Ogbonmwan, NIH F31 Predoctoral Diversity National Research Service Award2014-present Karl Schmidt, NIH F31 Predoctoral National Research Service Award2016-present Daniel F. Manvich, K99/R00 Pathway to Independence Award2016-present Kirsten A. Porter-Stransky, NIH F32 Postdoctoral National Research Service Award
Formal Teaching:
a. Medical Student Teaching: 2002 - 2007, MEDI 545, small group facilitator
a. Ph.D. students directly supervised for thesis work:1. Karen Rommelfanger, Neuroscience Graduate Program (received Ph.D. Spring, 2007, (currently Assistant Professor, Department of Neurology, Emory University School of Medicine and Program Director, Neuroethics Program, Emory University Center for Ethics, Atlanta, GA)2. Jesse Schank, Neuroscience Graduate Program (received Ph.D. Fall, 2008, currently Assistant Professor, Department of Physiology and Pharmacology, University of Georgia, Athens, GA)3. Kroshona Tabb, Neuroscience Graduate Program (received Ph.D. Fall, 2008, currently Data Manager, Birmingham VA Medical Center, Birmingham, AL)4. Heather Mitchell, Molecular/Systems Pharmacology Graduate Program (received Ph.D. Fall, 2010, currently Assistant Researcher, Rodent Models Core, Waisman Center, University of Wisconsin-Madison, Madison, WI)5. Meriem Gaval, Neuroscience Graduate Program (received Ph.D. Fall 2011, currently Regulatory Science Specialist, Cote Orphan LLC, Silver Spring, MD)6. S. Alisha Epps, Neuroscience Graduate Program (received Ph.D. Fall 2012, currently Assistant Professor, Department of Psychology, Whitworth University, Spokane, WA)7. Debra Cooper, Neuroscience Graduate Program (received Ph.D. Spring 2013, currently Consultant, California Senate Office of Research, Sacramento, CA).8. Yvonne Ogbonmwan, Neuroscience Graduate Program (received Ph.D. Spring 2015, currently postdoctoral fellow, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, T. Jovanovic, advisor) 9. Karl Schmidt, 6th year student, Neuroscience Graduate Program10. Termpanit Chalermpalanupap, 6th year student, Neuroscience Graduate Program11. Rachel Pearcy, 2nd year student, Neuroscience Graduate Program12. Stephanie Foster, 2nd year student, MD/PhD Program
Weinshenker, David 11Jessica McClung (Neuroscience Graduate Program, Summer, 2005)Sheena Brown (Molecular/Systems Pharmacology Graduate Program, Spring, 2006)Stacey Dutton (Neuroscience Graduate Program, Spring, 2006)Amy Mahan (Neuroscience Graduate Program, Fall, 2006)Dan Manvich (Neuroscience Graduate Program, Spring, 2006)Tonya Taylor (Molecular/Systems Pharmacology Graduate Program, Spring, 2006)S. Alisha Epps (Neuroscience Graduate Program, Spring, 2007)Kevin Ogden (Molecular/Systems Pharmacology Graduate Program, Fall, 2007)Nikki Sawyer (Neuroscience Graduate Program, Spring 2008)Megan Lyle (Neuroscience Graduate Program, Spring 2008)Becky Meyer (Neuroscience Graduate Program, Spring 2008)Debra Cooper (Neuroscience Graduate Program, Summer 2008)Sylvia Shabaya (Molecular/Systems Pharmacology Graduate Program, Fall, 2008)Angelica Trumer (Molecular/Systems Pharmacology Graduate Program, Fall, 2009)Yvonne Ogbonmwan (Neuroscience Graduate Program, Fall, 2009)Shawn Alter (Molecular/Systems Pharmacology Graduate Program, Spring 2010)Karl Schmidt (Neuroscience Graduate Program, Summer, 2010)Ellen Heath (Molecular/Systems Pharmacology Graduate Program, Fall 2010)Termpanit “Natty” Chalermpalanupap (Neuroscience Graduate Program, Spring 2011)Brilee Coleman (Molecular/Systems Pharmacology Graduate Program, Fall 2011)Ryan Purcell (Neuroscience Graduate Program, Spring 2012)Kara Kittelberger (Neuroscience Graduate Program, Spring 2012)Lauren Debrouse (Neuroscience Graduate Program, Spring 2012)Katherine Henry (Molecular/Systems Pharmacology Graduate Program, Summer 2012)Elizabeth Pitts (Neuroscience Graduate Program, Fall 2012)Kyle Gerber (Molecular/Systems Pharmacology Graduate Program, Summer 2013)Rachel Cliburn (Neuroscience Graduate Program, Fall 2013)Elizabeth Hinton (Neuroscience Graduate Program, Fall 2014)Alynda Wood (Neuroscience Graduate Program, Fall 2014)Miranda McDaniel (Molecular/Systems Pharmacology Graduate Program, Spring 2015)Cameron Herting (Molecular/Systems Pharmacology Graduate Program, Fall 2015)Makalele Gorsich (Neuroscience Graduate Program, Fall 2015)Sara Bramlett (Molecular/Systems Pharmacology Graduate Program, Winter 2015/2016)Rachel Pearcy (Neuroscience Graduate Program, Winter 2015/2016)Stephanie Foster (MD/PhD Program, Spring 2016)Yasmin Marrero-Garcia (Neuroscience Graduate Program, Summer 2016)
c. Post-doctoral fellows directly supervised:Melissa Marino, Ph.D., currently Science Writer/Information Officer, Vanderbilt University, Nashville, TNBrooke Bourdelat-Parks, Ph.D., currently Science Educator at the Biological Sciences Curriculum study, Colorado Springs, CO.Karen Rommelfanger, Ph.D., currently Assistant Professor, Department of Neurology, Emory University School of Medicine and Program Director, Neuroethics Program, Emory University Center for EthicsJason Schroeder, Ph.D., currently Research Assistant Professor, Department of Human Genetics, Emory UniversityDarlene Mitrano, Ph.D., currently Assistant Professor of Neurobiology, Christopher Newport University, Newport News, VA
Weinshenker, David 12Heather Mitchell, Ph.D., currently Assistant Researcher, Rodent Models Core, Waisman Center, University of Wisconsin-MadisonDaniel Manvich, Ph.D., Postdoctoral Fellow, Department of Human Genetics, Emory UniversityJacki Rorabaugh, Ph.D., Postdoctoral Fellow, Department of Human Genetics, Emory UniversityKirsten Porter-Stransky, Ph.D., Postdoctoral Fellow, Department of Human Genetics, Emory University
d. Undergraduate students supervised:Kathryn Parker, Co-Mentor for Honors thesis, 2006-2007Wenjie Xiao, Mentor for SIRE Fellowship, Honors thesis, 2008-2009 (awarded Highest Honors)Sharon Lin, Mentor for SURE Fellowship, 2009-2010 and Honors thesis, 2010-2011 (awarded Highest Honors)Anjani Chitrapu, Mentor for Honors thesis 2010-2011 (awarded Highest Honors)Daniel Puttick, Mentor for SIRE Fellowship, 2011-12Susan Lee, Mentor for SIRE Fellowship, 2011-12Janielle Taylor, Mentor for BRAIN/NETwork fellowship, 2011-12Daniel Puttick, Mentor for SURE Fellowship, 2012Taylor Stowe, Mentor for SURE and SIRE Fellowships, 2015Patrick Curtin, Mentor for Honors thesis, 2014-2015 (awarded High Honors)Katharine Henry, Mentor for SIRE Fellowship, 2014-2015
Outreach teaching:2003-2004, 2007 Judge, Atlanta Science and Mathematics Fair2003-present Taught at Atlanta area high schools during Brain Awareness Month
Invited Seminarsa. Local/regional
2002: Department of Pharmacology, Emory University, Atlanta, GA2004: Frontiers in Neuroscience, Emory University, Atlanta, GA2005: Ponce de Leon Center, Grady Hospital, Atlanta, GA2010: Frontiers in Neuroscience, Emory University, Atlanta, GA2011: Department of Physiology and Pharmacology, University of Georgia, Athens, GA2011: Neuroscience Institute, Georgia State University, Atlanta, GA2014: Department of Human Genetics, Emory University, Atlanta, GA2014: Neuroscience Ph.D. Program, University of Georgia, Athens, GA2015: Atlanta Science Festival, Emory University, Atlanta, GA2016: Department of Human Genetics, Emory University, Atlanta, GA
b. National/international2002: Department of Psychiatry, University of Texas Southwestern, Dallas, TX 2003: Department of Psychiatry, Yale University, New Haven, CT2004: Department of Neurodegenerative Disease, University of Bonn, Bonn, Germany2005: Cephalon Pharmaceuticals, Westchester, PA2005: Department of Biology, Williams College, Williamstown, MA2006: Department of Neurology, University of Münster, Münster, Germany2007: Department of Pharmacology, University of Pennsylvania, Philadelphia, PA2007: Committee on Neurobiology, University of Chicago, Chicago, IL
Weinshenker, David 142008: Department of Biochemistry, University of North Carolina, Chapel Hill, NC2008: Center for Advanced Nutrition, Utah State University, Logan, UT2010: Department of Neurobiology and Anatomy, Drexel University, Philadelphia, PA2012: Department of Neuroscience, Mt. Sinai Medical Center, New York, NY2012: Department of Biomedical Sciences, Marquette University, Milwaukee, WI2012: Department of Neurology, University of Bonn, Bonn, Germany2012: Department of Neurosciences, Medical University of South Carolina, Charleston, SC2013: Department of Psychology, University of Michigan, Ann Arbor, MI2013: National Institute of Environmental Health Sciences, Research Triangle Park, NC2014: Department of Anesthesiology, Washington University, St. Louis, MO2015: Department of Biology, Williams College, Williamstown, MA2016: Neuroscience Graduate Program, University of Texas-San Antonio, San Antonio, TX2016: McLean Hospital, Harvard Medical School, Belmont, MA
c. National/international conferences2004: Winter Conference for Brain Research, Copper Mountain, CO2005: Banbury Conference on Epilepsy, Cold Spring Harbor, NY2005: American College of Neuropsychopharmacology Annual Meeting, Kona, HI2006: International Conference on Alzheimer’s Disease Drug Discovery, New York, NY2006: Society for Neuroscience Annual Meeting, IDARS Satellite on Drug Addiction, Atlanta, GA2008: International Symposium on Dietary Therapies for Epilepsy and Other Neurological Disorders, Phoenix, AZ2009: Gordon Conference on Catecholamines, University of New England, Biddeford, ME2011: Panel Discussion Leader, Gordon Research Conference on Catecholamines, Lewiston, ME2011: Panel Discussion Leader, Gordon Research Graduate Seminar on Catecholamines, Lewiston, ME2011: Winter Conference for Brain Research, Keystone, CO2013: Winter Conference for Brain Research, Breckenridge, CO2013: Gordon Conference on Catecholamines, West Dover, VT2013: Panel Discussion Leader, Gordon Research Graduate Seminar on Catecholamines, West Dover, VT2014: Julius Axelrod Symposium, Experimental Biology Annual Meeting, San Diego, CA2014: Society for Neuroscience Annual Meeting, Washington, DC2014: American College of Neuropsychopharmacology Annual Meeting, Phoenix, AZ2015: Vice Chair, Gordon Research Conference on Catecholamines, Newry, NE2017: Future Chair, Gordon Research Conference on Catecholamines, Newry, NE
Bibliography
a. Published and accepted research articles in refereed journals:1. Weinshenker D, Garriga G, Thomas JH (1995) Genetic and pharmacological analysis of neurotransmitters controlling egg laying in C. elegans. J Neurosci 15:6975-6985. PMID: 7472454.
2. Reiner DJ, Weinshenker D, Thomas JH (1995) Analysis of dominant mutations affecting muscle excitation in Caenorhabditis elegans. Genetics 141:961-976. PMCID: PMC1206858.
3. Weinshenker D, Wei A, Salkoff L, Thomas JH (1999) Block of an ether-a-go-go-like K(+) channel by imipramine rescues egl-2 excitation defects in Caenorhabditis elegans. J Neurosci 19:9831-9840. PMID: 10559392. Figure 5e from this manuscript was selected for the cover of this issue.
Weinshenker, David 15
4. Szot P, Weinshenker D, White SS, Robbins CA, Rust NC, Schwartzkroin PA, Palmiter RD (1999) Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli. J Neurosci 19:10985-92. PMID: 10594079.
6. Weinshenker D, Szot P, Miller NS, Rust NC, White SS Palmiter RD (2001) Genetic Comparison of Seizure Control by Norepinephrine and Neuropeptide Y. J Neurosci 21:7764-7769. PMID: 11567066.
7. Szot P, Weinshenker D, Rho JM, Storey TW, Schwartzkroin PA (2001) Norepinephrine is required for the anticonvulsant effect of the ketogenic diet. Brain Res Dev Brain Res 129:211-214. PMID: 11506865.
8. Weinshenker D, Szot P, Miller NS, Palmiter RD (2001) 1 and 2 Adrenoreceptor Agonists Inhibit Pentylenetetrazole-Induced Seizures in Mice Lacking Norepinephrine. J Pharmacol Exp Ther 298:1042-1048. PMID: 11504801.
9. Jasmin L, Tien D, Weinshenker D, Palmiter RD, Green PG, Janni G, Ohara PT (2002) The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline. Proc Nat Acad Sci USA 99:1029-1034. PMCID: PMC117425.
10. Weinshenker D, White SS, Javors MA, Palmiter RD, Szot P (2002) Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo. Brain Res 946:239-246. PMID: 12137927. PMID: 12370425
11. Weinshenker D, Miller NS, Blizinsky K, Laughlin ML, Palmiter RD (2002) Mice with chronic norepinephrine deficiency resemble amphetamine-sensitized animals. Proc Nat Acad Sci USA 99:13873-13877. PMCID: PMC129790.
12. Swoap SJ, Weinshenker D, Palmiter RD, Garber G (2004) Dbh(-/-) mice are hypotensive, have altered circadian rhythms, and have abnormal responses to dieting and stress. Am J Physiol Regul Integr Comp Physiol 286:R108-R113. PMID: 12969876.
13. Hohmann JG, Teklemichael DN, Weinshenker D, Wynick D, Clifton DK, Steiner RA (2004) Obesity and endocrine dysfunction in mice with deletions of both neuropeptide Y and galanin. Mol Cell Biol 24:2978-2985. PMCID: PMC371109.
14. Szot P, Lester M, Laughlin ML, Liles LC, Palmiter RD, Weinshenker D (2004) The anticonvulsant and proconvulsant effects of 2-adrenoreceptor agonists are mediated by distinct populations of 2A-adrenoreceptors. Neuroscience 126:795-803. PMID: 15183527.
15. Tabb K, Szot P, White SS, Liles LC, Weinshenker D (2004) The ketogenic diet does not alter brain expression of orexigenic neuropeptides. Epilepsy Res 62:35-39. PMID: 15519130.
16. Depondt C, Cock HR, Healy DG, Burley MW, Weinshenker D, Wood NW, Goldstein DB, Sisodiya SM (2004) The -1021C->T DBH gene variant is not associated with epilepsy or antiepileptic drug response. Neurology 63:1497-149. PMID: 15505174.
18. Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El-Ghundi M, O’Dowd BF, George SR, Perreault ML, Mannisto PT, Robinson S, Palmiter RD, Tallerico T (2005) Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc Natl Acad Sci USA 102: 3513-3518. PMCID: PMC548961.
19. Marino MD, Bourdélat-Parks BN, Weinshenker D (2005) Genetic reduction of noradrenergic function alters social memory and reduces aggression in mice. Behav Brain Res 161:197-203. PMID: 15922045.
20. Gottsch ML, Zeng H, Hohmann JG, Weinshenker D, Clifton DK, Steiner RA (2005) Phenotypic analysis of mice deficient in the type 2 galanin receptor (GALR2). Mol Cell Biol 25:4804-4811. PMCID: PMC1140643.
21. Schank JR, Liles LC, Weinshenker D (2005) Norepinephrine is required for the full anticonvulsant effects of valproic acid in mice. Epilepsy Res 65:23-31. PMID: 15955669.
22. Weinshenker D, Wilson MM, Williams KM, Weiss JM, Lamb NE, Twigger SN (2005) A new method for identifying informative genetic markers in selectively bred rats. Mamm Genome 16:784-791. PMID: 16261420.
23. Bourdelat-Parks B, Anderson, GM, Donaldson ZR, Weiss JM, Bonsall RW, Emery MS, Liles LC, Weinshenker D (2005) Effects of dopamine -hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology 183:72-80. PMID: 16163519.
24. Schank JR, Ventura R, Puglisi-Allegra S, Alcaro A, Cole CD, Liles LC, Seeman P, Weinshenker D (2006) Dopamine -hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology 31:2221-2230. PMID: 16395294.
25. Swoap SJ, Gutilla MJ, Liles LC, Smith RO, Weinshenker D (2006) The full expression of fasting-induced torpor in mice requires beta-3 adrenergic receptor signaling. J Neurosci 26:241-245. PMID: 16399693.
26. Olson VG, Heusner CL, Bland RJ, During MJ, Weinshenker D, Palmiter RD. (2006) Role of noradrenergic signaling by the nucleus tractus solitarius in mediating opiate reward. Science 311:1017-1020. PMID: 16484499.
27. Martillotti J, Weinshenker D, Liles LC, Eagles DA (2006) A ketogenic diet and knockout of the norepinephrine transporter both reduce seizure severity in mice. Epilepsy Res 68:207-211. PMID: 16356685.
28. Ahern T, Javors MA, Eagles DA, Martillotti J, Mitchell HA, Liles LC, Weinshenker D (2006) The effects of chronic norepinephrine transporter inactivation on seizure susceptibility in mice. Neuropsychopharmacology 31:730-738. PMID: 16052243.
Weinshenker, David 17
29. Mitchell HA, Ahern TH, Liles LC, Javors MA, Weinshenker D (2006) The effects of norepinephrine transporter inactivation on locomotor activity in mice. Biol Psych 60:1046-1052. PMID: 16893531.
31. Sanders JD, Szot P, Weinshenker D, Happe HK, Bylund DB, Murrin LC (2006) Analysis of brain adrenergic receptors in dopamine -hydroxylase knockout mice. Brain Res 1109:45-53. PMID: 16854392.
32. Sowden GL, Drucker DJ, Weinshenker D, Swoap SJ (2007) Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. Am J Physiol Regul Integr Comp Physiol 292:R962-970. PMID: 17038440.
33. Paladini CA, Beckstead MJ, Weinshenker D (2007) Electrophysiological properties of catecholaminergic neurons in the norepinephrine-deficient mouse. Neuroscience 144:1067-1074. PMCID: PMC1847415.
34. Tabb KD, Boss-Williams KA, Weiss JM, Weinshenker D (2007) Rats bred for susceptibility to depression-like phenotypes have higher kainic acid-induced seizure mortality than their depression-resistant counterparts. Epilepsy Res 74:140-146. PMCID: PMC1940038.
35. Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D (2007) Norepinephrine loss produces more profound motor deficits than MPTP in mice. Proc Natl Acad Sci USA 104:13804-13809. PMCID: PMC1959463.
37. Schank JR, Liles LC, Weinshenker D (2008) Norepinephrine signaling through -adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol Psych 63:1007-1012. PMCID: PMC2405894.
36. Weinshenker D, Ferrucci M, Busceti CL, Biagioni F, Lazzeri G, Liles LC, Lenzi P, Pasquali L, Murri L, Paparelli A, Fornai F (2008) Genetic or pharmacological blockade of noradrenaline synthesis enhances the neurochemical, behavioural, and neurotoxic effects of methamphetamine. J Neurochem 105:471-483. PMCID: PMC2610530.
38. Gaval-Cruz M, Schroeder JP, Liles LC, Javors MA, Weinshenker D (2008) Effects of disulfiram and dopamine beta-hydroxylase knockout on cocaine-induced seizures. Pharmacol Biochem Behav 89:556-562. PMCID: PMC2386143.
39. Lin Y, Quartermain D, Dunn AJ, Weinshenker D, Stone EA (2008) Possible dopaminergic stimulation of locus coeruleus alpha1-adrenoceptors involved in behavioral activation. Synapse 62:516-523. PMCID: PMC2754581
40. Mitchell HA, Bogenpohl JW, Liles LC, Epstein MP, Bozyczko-Coyne D, Williams M, Weinshenker D (2008) Behavioral responses of dopamine -hydroxylase knockout mice to
Weinshenker, David 18modafinil suggest a dual noradrenergic-dopaminergic mechanism of action. Pharmacol Biochem Behav 91:217-222. PMCID: PMC2597705.
41. Swoap SJ, Weinshenker D (2008) Norepinephrine controls both torpor initiation and emergence via distinct mechanisms in the mouse. PLoS One 3:e4038. PMCID: PMC2602851.
42. Rommelfanger KS, MItrano DA, Smith Y, Weinshenker D (2009) Light and electron microscopic localization of alpha-1 adrenergic receptor immunoreactivity in the rat striatum and ventral midbrain. Neuroscience 158:1530-1540. PMCID: PMC2692639.
43. Goldenstein BL, Nelson BW, Xu K, Luger EJ, Pribula JA, Wald JM, O'Shea LA, Weinshenker D, Charbeneau RA, Huang X, Neubig RR, Doze VA (2009) RGS Protein Suppression of G{alpha}o Protein-Mediated {alpha}2A Adrenergic Receptor Inhibition of Mouse Hippocampal CA3 Epileptiform Activity. Mol Pharmacol 75:1222-1230. PMCID: PMC2672807.
44. Xiao Z, Deng PY, Rojanathammanee L, Yang C, Grisanti L, Permpoonputtana K, Weinshenker D, Doze VA, Porter JE, Lei S (2009) Noradrenergic depression of neuronal excitability in the entorhinal cortex via activation of TREK-2 K+ channels. J Biol Chem 284:10980-10991. PMCID: PMC2667783.
45. Gilsbach R, Röser C, Beetz N, Brede M, Hadamek K, Haubold M, Leemhuis J, Philipp M, Schneider J, Urbanski M, Szabo B, Weinshenker D, Hein L (2009) Genetic dissection of alpha2-adrenoceptor functions in adrenergic versus nonadrenergic cells. Mol Pharmacol 75:1160-1170. PMID: 19251826.
46. Taylor TN, Caudle WM, Shepherd KR, Noorian A, Jackson CR, Iuvone PM, Weinshenker D, Greene JG, Miller GW (2009) Nonmotor symptoms of Parkinson’s disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 29:8103-8113. PMCID: PMC2813143.
47. Jang SW, Liu X, Chan CB, Weinshenker D, Hall RA, Xiao G, Ye K (2009) Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol 16:644-656. PMCID: PMC2844702.
48. Yanpallewar SU, Fernandes K, Marathe SV, Vadodaria KC, Jhaveri D, Rommelfanger K, Ladiwala U, Jha S, Muthig V, Hein L, Bartlett P, Weinshenker D, Vaidya VA (2009) 2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment. J Neurosci 30:1096-1109. PMCID: PMC2880491.
49. Moreira CG, Weinshenker D, Sperandio V (2010) QseC mediates Slamonella enterica serovar Typhimurium virulence in vitro and in vivo. Infect Immun 78:914-926. PMCID: PMC2825943.
50. Skinbjerg M, Seneca N, Liow JS, Hong J, Weinshenker D, Pike VW, Halldin C, Sibley DR, Innis RB (2010) Dopamine -hydroxylase-deficient mice have normal densities of D2 dopamine receptors in the high affinity state based on in vivo PET imaging and in vitro radioligand binding. Synapse 64:699-703. PMCID: PMC2894264.
51. Schroeder JP, Cooper DA, Schank JR, Lyle MA, Gaval-Cruz M, Ogbonmwan YE, Pozdeyev N, Freeman KG, Iuvone PM, Edwards GL, Holmes PV, Weinshenker D (2010) Disulfiram Attenuates
Weinshenker, David 19Drug-Primed Reinstatement of Cocaine Seeking via Inhibition of Dopamine beta-Hydroxylase. Neuropsychopharmacology 35:2440-2449. PMCID: PMC2956132.
52. Lee SE, Simons SB, Heldt SA, Zhao M, Schroeder JP, Vellano CP, Cowan DP, Ramineni S, Yates CK, Feng Y, Smith Y, Sweatt JD, Weinshenker D, Ressler KJ, Dudek SM, Hepler JR (2010) RGS14 is a natural suppressor of both synaptic plasticity in CA2 neurons and hippocampal-based learning and memory. Proc Natl Acad Sci USA 107:16994-16998. PMCID: PMC2947872.
53. Keebaugh AC, Mitchell HA, Gaval-Cruz M, Freeman KG, Edwards GL, Weinshenker D, Thomas JW (2011) PRTFDC1 is a genetic modifier of HPRT-deficiency in the mouse. PLoS One 6:e22381. PMCID: PMC3144895.
54. Rovin ML, Boss-Williams KA, Alisch RS, Ritchie JC, Weinshenker D, West CH, Weiss JM (2012) Influence of chronic administration of antidepressant drugs on mRNA for galanin, galanin receptors, and tyrosine hydroxylase in catecholaminergic and serotonergic cell-body regions in rat brain. Neuropeptides 46:81-91. PMID: 22317959.
55. Mitrano DA, Schroeder JP, Smith Y, Cortright JJ, Bubula N, Vezina P, Weinshenker D (2012) 1-adrenergic receptors are localized on presynaptic elements in the nucleus accumbens and regulate mesolimbic dopamine transmission. Neuropsychopharmacology 37:2161-2172. PMCID: PMC3398716. Figure 4b from this manuscript was selected for the cover of this issue.
56. Baker C, Taylor DG, Osuala K, Natarajan A, Molnar PJ, Hickman J, Alam S, Moscato B, Weinshenker D, Ebert SN (2012) Adrenergic deficiency leads to impaired electrical conduction and increased arrhythmic potential in the embryonic mouse heart. Biochem Biophys Res Comm 423:536-541. PMID: 22683331.
57. Epps SA, Tabb KD, Lin SJ, Kahn AB, Javors MA, Boss-Williams KA, Weiss JM, Weinshenker D (2012) Seizure susceptibility and epileptogenesis in a rat model of epilepsy and depression comorbidity. Neuropsychopharmacology 37:2756-2763. PMCID: PMC3499730.
58. Hammerschmidt T, Kummer MP, Terwel D, Martinez A, Gorji A, Pape HC, Rommelfanger KS, Schroeder JP, Stoll M, Schultze J, Weinshenker D, Heneka MT (2012) Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice. Biol Psych 73:454-463. PMID: 22883210.
59. Osuala K, Nguyen HL, Martinez C, Weinshenker D, Ebert SN (2012) Adrenergic hormone deficiency leads to increased embryonic retinoic acid concentrations during a critical phase of heart development. Physiol Genomics 44:934-947. PMCID: PMC3472461.
60. Lin SJ, Epps SA, West CH, Boss-Williams KA, Weiss JM, Weinshenker D (2012) Operant psychostimulant self-administration in a rat model of depression. Pharmacol Biochem Behav 103:380-385. PMCID: PMC3494799.
61. Gaval-Cruz M, Liles LC, Iuvone PM, Weinshenker D (2012) Chronic inhibition of dopamine -hydroxylase facilitates behavioral responses to cocaine in mice. PLoS One 7:e50583. PMCID: PMC3507785.
Weinshenker, David 2062. Schroeder JP, Epps SA, Grice TW, Weinshenker D (2013) The selective dopamine -hydroxylase inhibitor nepicastat attenuates multiple aspects of cocaine-seeking behavior. Neuropsychopharmacology 38:1032-1038. PMCID: PMC3629392.
63. Purcell RH, Papale LA, Makinson CD, Sawyer NT, Schroeder JP, Escayg A, Weinshenker D (2013) Effects of an epilepsy-causing mutation in the SCN1A sodium channel gene on cocaine-induced seizure susceptibility in mice. Psychopharmacology 228:263-270. PMCID: PMC3695079.
64. Epps SA, Kahn AB, Holmes PV, Boss-Williams KA, Weiss JM, Weinshenker D (2013) Antidepressant and anticonvulsant effects of exercise in a rat model of epilepsy and depression comorbidity. Epilepsy Behav 29:47-52. PMCID: PMC3783960.
65. Manvich DF, DePoy LM, Weinshenker D (2013) Dopamine -hydroxylase inhibitors enhance the discriminative stimulus effects of cocaine in rats. J Pharmacol Exp Ther 347:564-573. PMCID: PMC3836309.
66. Zhang Z, Liu X, Schroeder JP, Chan CB, Song M, Yu SP, Weinshenker D, Ye K (2014) 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 39:638-650. PMCID: PMC3895241.
67. Schank JR, King CE, Sun H, Cheng K, Rice KC, Heilig M, Weinshenker D, Schroeder JP (2014) The role of the neurokinin-1 receptor in stress-induced reinstatement of alcohol and cocaine seeking. Neuropsychopharmacology 39:1093-1101. PMCID: PMC3957103
68. Mitrano DA, Pare JF, Smith Y, Weinshenker D (2014) D1-dopamine and 1-adrenergic receptor co-localize in dendrites of the rat prefrontal cortex. Neuroscience 258C:90-100. PMCID: PMC3913162.
69. Heldt SA, Zimmermann K, Parker K, Gaval M, Weinshenker D, Ressler KJ (2014) Bdnf Deletion or TrkB Impairment in Amygdala Inhibits Both Appetitive and Aversive Learning. J Neurosci 34:2444-2450, correction in J Neurosci 34:4756. PMCID: PMC3921419.
70. Kummer MP, Hammerschmidt T, Martinez A, Terwel D, Eichele G, Witten A, Figura S, Stoll M, Schwartz S, Pape HC, Schultze JL, Weinshenker D, Heneka MT (2014) Ear2 deletion causes early memory and learning deficits in APP/PS1 mice. J Neurosci 34:8845-8854. PMCID: PMC4147626.
71. Cooper DA, Kimmel HL, Manvich DF, Schmidt KT, Weinshenker D, Howell LL (2014) Effects of pharmacologic dopamine -hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys. J Pharmacol Exp Ther 350:144-152. PMCID: PMC4056266.
72. Barrie ES, Weinshenker D, Verma A, Pendergrass SA, Lange LA, Ritchie MD, Wilson JG, Kuivaniemi H, Tromp G, Carey DJ, Gerhard GS, Brilliant MH, Hebbring SJ, Cubells JF, Pinsonneault JK, Normal GJ, Sadee W (2014) Regulator polymorphisms in human DBH affect peripheral gene expression and sympathetic activity. Circ Res 115:1017-1025. PMCID: PMC4258174.
73. Liu X, Ye K, Weinshenker D (2015) Norepinephrine protects against A toxicity via TrkB. J Alzheimer Dis 44:251-260. PMCID: PMC4714587.
Weinshenker, David 21
74. Ogbonmwan YE, Sciolino NR, Groves-Chapman JL, Freeman KG, Schroeder JP, Edwards GL, Holmes PV, Weinshenker D (2015) The Galanin Receptor Agonist, Galnon, Attenuates Cocaine-Induced Reinstatement and Dopamine Overflow in the Frontal Cortex. Addict Biol 20:701-713. PMCID: PMC4305031.
75. Sciolino NR, Smith JM, Stranahan AM, Freeman KG, Edwards GL, Weinshenker D, Holmes PV (2015) Galanin mediates features of neural and behavioral stress resilience afforded by exercise. Neuropharmacology 89:255-64. PMCID: PMC4250306.
76. Ogbonmwan YE, Schroeder JP, Holmes PV, Weinshenker D (2015) The effects of post-extinction exercise on cocaine-primed and stress-induced reinstatement of cocaine seeking in rats. Psychopharmacology 232:1395-1403. PMCID: PMC4388768.
77. Shepard KN, Liles LC, Weinshenker D, Liu R (2015) Norepinephrine is necessary for experience-dependent plasticity in the developing mouse auditory cortex. J Neurosci 35:3432-2437. PMCID: PMC4323528.
78. Manvich DF, Stowe TA, Godfrey JR, Weinshenker D (2015) A method for psychosocial stress-induced reinstatement of cocaine seeking in rats. Biol Psychiatry [Epub ahead of print 7/8/15]. PMCID: PMC4706515.
79. Gokhale A, Vrailas-Mortimer A, Larimore J, Comstra HS, Zlatic SA, Werner E, Manvich DF, Iuvone PM, Weinshenker D, Faundez V (2015) Neuronal copper homeostasis instability by genetic defects in dysbindin, a schizophrenia susceptibility factor. Hum Mol Genetic 24:5512-5523. PMCID: PMC4572075.
80. Rose SJ, Yu XY, Heinzer AK, Harrast P, Fan X, Raike RS, Thompson VB, Pare JF, Weinshenker D, Smith Y, Jinnah HA, Hess EJ (2015) A new knockin mouse model of L-DOPA-responsive dystonia. Brain 138:2987-3002. PMCID: MPC4627353.
81. Gaval-Cruz M, Goertz RB, Puttick DJ, Bowles DE, Meyer RC, Hall RA, Paladini CA, Weinshenker D (2016) Chronic loss of noradrenergic tone produces -arrestin2-mediated cocaine hypersensitivity and alters cellular D2 responses in the nucleus accumbens. Addict Biol 21:35-48. PMCID: PMC4326638.
82. Cubells JF, Schroder JP, Barrie ES, Manvich DF, Sadee W, Berg T, Mercer K, Stowe TA, Liles LC, Squires KE, Mezher A, Cuertin P, Perdomo DL, Szot P, Weinshenker D (2016) Human bacterial artificial chromosome (BAC) transgenesis fully rescues noradrenergic function in dopamine -hydroxylase knockout mice. PLoS One 11:e0154864. PMCID: PMC4857931.
83. Gyoneva S, Swanger SA, Zhang J, Weinshenker D, Tranelis SF (2016) Altered motility of plaque-associated microglia in a model of Alzheimer’s disease. Neuroscience [Epub ahead of print 8/25/16]. PMCID: PMC4927418.
84. Moreira CG, Russell R, Mishra AA, Narayanan S, Ritchie JM, Waldor MK, Curtis MM, Winter SE, Weinshenker D, Sperandio V (2016) Bacterial adrenergic sensors regulate virulence of enteric pathogens in the gut. mBio 7.
Weinshenker, David 22b. Manuscripts submitted:
c. Review Articles and Commentaries:
1. Weinshenker D, Szot P (2002) The role of catecholamines in seizure susceptibility: new results using genetically engineered mice. Pharmacol Ther 94:213-233. PMID: 12113799.
3. Weinshenker D, Schroeder JP (2006) There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology 32:1433-1451. PMID: 17164822.
4. Rommelfanger KS, Weinshenker D (2007) Norepinephrine: the redheaded stepchild of Parkinson’s disease. Biochem Pharmacol 74:177-190. PMID: 17416354.
5. Weinshenker D (2008) Functional consequences of locus coeruleus degeneration in Alzheimer’s disease. Curr Alzheimer Res 5:342-345. PMID: 18537547.
6. Weinshenker D (2008) The contribution of norepinephrine and orexigenic neuropeptides to the anticonvulsant effect of the ketogenic diet. Epilepsia 49 (Suppl 8):104-107. PMID: 19049603.
8. Gaval-Cruz M, Weinshenker D (2009) Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol Interv 9:175-187. PMCID: PMC2861803.
9. Mitchell HA, Weinshenker D (2010) Good night and good luck: norepinephrine in sleep pharmacology. Biochem Pharmacol 79:801-809. PMCID: PMC2812689.
10. Weinshenker D (2010) Cocaine sobers up. Nat Med 16:969-970. PubMed PMID: 20823878.
11. Epps SA, Weinshenker D (2013) Rhythm and blues: animal models of depression and epilepsy comorbidity. Biochem Pharmacol 85:135-146. PMID: 22940575.
12. Chalermpalanupap T, Kinkead B, Hu WT, Kummer MP, Hammerschmidt T, Heneka MT, Weinshenker D, Levey AI (2013) Targeting norepinephrine in mild cognitive impairment and Alzheimer’s disease. Alzheimers Res Ther 5:21. PMCID: PMC3706916.
13. Schmidt KT, Weinshenker D (2014) Adrenaline rush: The role of adrenergic receptors in stimulant-induced behaviors. Mol Pharmacol 85:640-650. PMCID: PMC3965894.
14. Weinshenker D, Holmes PV (2015) Regulation of neurological and neuropsychiatric phenotypes by locus coeruleus-derived galanin. Brain Res [Epub 11/20/15]. PMID 26607256 (PMC in process).
d. Book Chapters:
Weinshenker, David 23
1. Weinshenker D (2004) Galanin and neuropeptide Y: Orexigenic neuropeptides link food intake, energy homeostasis, and seizure susceptibility. In Epilepsy and the ketogenic diet (C.E. Stafstrom and J.M. Rho, eds.), Humana, Totawa, NJ, pp. 279-287.
2. Weinshenker D (2008) Treatment, Pharmacological Approaches to: Clonidine. In Encyclopedia of Drugs, Alcohol, and Addictive Behavior, 3rd ed. (P. Korsmeyer and H. Kranzler, eds.), Macmillan Reference USA, Farmington Hills, MI.
3. Weinshenker D (2008) Clone, Cloning. In Encyclopedia of Drugs, Alcohol, and Addictive Behavior, 3rd ed. (P. Korsmeyer and H. Kranzler, eds.), Macmillan Reference USA, Farmington Hills, MI.
4. Weinshenker D, Tabb K, Szot P (2009) Norepinephrine: a molecular link between epilepsy and depression? In Encylopedia of Basic Epilepsy Research (P. Schwartzkroin, ed.), Elsevier, Academic Press.
5. Weinshenker D (2012) Functional Consequences of Locus Coeruleus Degeneration in Alzheimer’s Disease. In Advances in Alzheimer Research (D.K. Lahiri, ed.), Bentham Science Publishers, Oak Park, IL.
